Loading...
Although the autosomal dominant form of early-onset Alzheimer disease (AD; onset at or before age 60) is often recognized because of family history, sporadic cases are less frequently identified in the early stages of the illness. In a retrospective case review of 40 patients with autopsy-proven early-onset AD (age range, 46–60; mean age, 54; mean duration of illness, 11 years), researchers highlight diagnostic pitfalls in this subpopulation. Clinical histories were provided by the diagnosing clinicians who had managed the patients during their illness. Pathologic assessments and genetic testing for APOE alleles were conducted in autopsy specimens.
Overall, 62% of patients presented with typical episodic memory dysfunction, and 38% first presented with predominantly nonmemory symptoms, including frontal dysfunction (behavioral dyscontrol, executive dysfunction, or both); language deficits; or posterior variants (visuospatial dysfunction, praxis deficits, or both). Regardless of the presenting symptoms, mean delay to diagnosis was 3.1 years. Initial clinical misdiagnoses were made in 53% of patients with atypical presentations and 4% of patients who presented with memory deficits. Final clinical misdiagnosis rates remained significantly different (atypical, 47%; typical, 4%). Patients with family histories of AD were more than three times as likely as those without such histories to carry APOE*E4 alleles; however, APOE status had no significant relation to clinical presentation.
Balasa M et al. Clinical features and APOE genotype of pathologically proven early-onset Alzheimer disease. Neurology 2011 May 17; 76:1720.
Comment
Although limited by its retrospective methodology and selection bias in autopsied cases, the findings from this series serves as an incisive reminder that AD remains an important consideration in the differential diagnosis of young-onset dementia; moreover, AD can have protean manifestations in this population. Given that clinical features have substantial overlap across a range of neurodegenerative diseases, this study highlights the need for reliable in vivo biomarkers to confirm initial diagnostic impressions, particularly as disease-modifying therapies are in development.